Is enzalutamide (enzalutamide) a chemotherapy drug or a targeted drug?

Enzalutamide (Enzalutamide) is a targeted therapy, not a chemotherapy drug. Targeted drugs refer to drugs that can act on specific molecular targets in tumor cells to inhibit the growth and spread of tumor cells, unlike traditional chemotherapy drugs that affect the growth and division of normal cells.

Enzalutamide's mechanism of action is to exert anti-tumor effects by inhibiting androgen receptors (Androgen Receptor, AR). In prostate cancer, the androgen receptor is a key promoter that drives tumor cells to grow and spread. Enzalutamide By binding to the androgen receptor, it prevents the binding of androgens and inhibits their activity, thereby inhibiting the growth and spread of prostate cancer cells and prolonging the survival of patients.

Compared with traditional chemotherapy drugs, targeted drugs such as enzalutamide (enzalutamide) usually have a more specific mechanism of action, so they can reduce the toxic side effects during treatment to a certain extent and improve the quality of life of patients. In addition, because targeted drugs target specific molecular targets in tumor cells, they are more selective for a patient's tumor cells, which can improve the effectiveness of treatment.

In general, enzalutamide (enzalutamide) is a targeted therapy drug mainly used to treat advanced prostate cancer. Its mechanism of action is to inhibit the growth and spread of tumor cells by inhibiting the androgen receptor. The use of targeted drugs provides a more effective and safer treatment option for prostate cancer patients, which can improve patients' survival and quality of life.